Literature DB >> 15277237

B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.

Noriko Asano1, Manabu Fujimoto, Norihito Yazawa, Senji Shirasawa, Minoru Hasegawa, Hitoshi Okochi, Kunihiko Tamaki, Thomas F Tedder, Shinichi Sato.   

Abstract

Systemic sclerosis (SSc) is characterized by fibrosis and autoimmmunity. Peripheral blood B cells from SSc patients specifically overexpress CD19, a critical cell-surface signal transduction molecule in B cells. CD19 deficiency in B cells also attenuates skin fibrosis in the tight-skin (TSK/+) mouse, a genetic model for SSc. Herein we analyzed two transgenic mouse lines that overexpress CD19. Remarkably, 20% increase of CD19 expression in mice spontaneously induced SSc-specific anti-DNA topoisomerase I (topo I) antibody (Ab) production, which was further augmented by 200% overexpression. In TSK/+ mice overexpressing CD19, skin thickness did not increase, although anti-topo I Ab levels were significantly augmented, indicating that abnormal CD19 signaling influences autoimmunity in TSK/+ mice and also that anti-topo I Ab does not have a pathogenic role. The molecular mechanisms for abnormal CD19 signaling were further assessed. B-cell antigen receptor crosslinking induced exaggerated calcium responses and augmented activation of extracellular signal-regulated kinase in TSK/+ B cells. CD22 function was specifically impaired in TSK/+ B cells. Consistently, CD19, a major target of CD22-negative regulation, was hyperphosphorylated in TSK/+ B cells. These findings indicate that reduced inhibitory signal provided by CD22 results in abnormal activation of signaling pathways including CD19 in TSK/+ mice and also suggest that this disrupted B cell signaling contribute to specific autoantibody production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277237      PMCID: PMC1618564          DOI: 10.1016/S0002-9440(10)63328-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  54 in total

1.  Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection.

Authors:  R J Cornall; J G Cyster; M L Hibbs; A R Dunn; K L Otipoby; E A Clark; C C Goodnow
Journal:  Immunity       Date:  1998-04       Impact factor: 31.745

2.  CD22 is a negative regulator of B-cell receptor signalling.

Authors:  L Nitschke; R Carsetti; B Ocker; G Köhler; M C Lamers
Journal:  Curr Biol       Date:  1997-02-01       Impact factor: 10.834

3.  Functional dissection of systemic lupus erythematosus using congenic mouse strains.

Authors:  L Morel; C Mohan; Y Yu; B P Croker; N Tian; A Deng; E K Wakeland
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

4.  CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19.

Authors:  S Sato; D A Steeber; P J Jansen; T F Tedder
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

5.  An open study of B lymphocyte depletion in systemic lupus erythematosus.

Authors:  Maria J Leandro; Jonathan C Edwards; Geraldine Cambridge; Michael R Ehrenstein; David A Isenberg
Journal:  Arthritis Rheum       Date:  2002-10

6.  Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses.

Authors:  X Wang; A Kumanogoh; C Watanabe; W Shi; K Yoshida; H Kikutani
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

7.  B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene.

Authors:  K N Kasturi; A Hatakeyama; C Murai; R Gordon; R G Phelps; C A Bona
Journal:  J Autoimmun       Date:  1997-12       Impact factor: 7.094

8.  Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes.

Authors:  N Razi; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

9.  The Tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils.

Authors:  C M Kielty; M Raghunath; L D Siracusa; M J Sherratt; R Peters; C A Shuttleworth; S A Jimenez
Journal:  J Cell Biol       Date:  1998-03-09       Impact factor: 10.539

10.  The motheaten mutation rescues B cell signaling and development in CD45-deficient mice.

Authors:  G Pani; K A Siminovitch; C J Paige
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

View more
  26 in total

Review 1.  T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities.

Authors:  Francesco Del Galdo; Carol M Artlett
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

2.  The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis.

Authors:  Giacomo De Luca; Alessandro Tomelleri; Lorenzo Dagna; Marco Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2021-05-22       Impact factor: 2.980

3.  Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis.

Authors:  Konstantinos Melissaropoulos; Stamatis-Nick Liossis
Journal:  Rheumatol Int       Date:  2018-06-04       Impact factor: 2.631

4.  B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.

Authors:  Minoru Hasegawa; Yasuhito Hamaguchi; Koichi Yanaba; Jean-David Bouaziz; Junji Uchida; Manabu Fujimoto; Takashi Matsushita; Yukiyo Matsushita; Mayuka Horikawa; Kazuhiro Komura; Kazuhiko Takehara; Shinichi Sato; Thomas F Tedder
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

5.  Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response.

Authors:  Takashi Matsushita; Manabu Fujimoto; Minoru Hasegawa; Kazuhiro Komura; Kazuhiko Takehara; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

Review 6.  Animal models in scleroderma.

Authors:  Stephen H Clark
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

7.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

Review 8.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

9.  The role of B cells in systemic sclerosis.

Authors:  Marina D Kraaij; Jacob M van Laar
Journal:  Biologics       Date:  2008-09

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.